Table 1.
Type of front-line induction regimen and characteristics of patients at first relapse.
| Charac teristic | No. (%) | Median (range) | VMP Induction n=67 (%) | VTP Induction n=78 (%) |
|---|---|---|---|---|
| Male | 69 (47.6) | 33 (49.3) | 36 (46.2) | |
| Age (years) | 74.4 (66 –87.5) | 74.5 (66–87.5) | 74.3 (66.3–87.2) | |
| M protein | ||||
| IgG | 80 (57.6) | 38 (60.3) | 42 (55.3) | |
| IgA | 43 (30.9) | 20 (31.7) | 23 (30.3) | |
| Light chain | 16 (11.5) | 5 (7.9) | 11 (14.5) | |
| ISS stage | ||||
| 1 | 35 (29.7) | 15 (28.3) | 20 (30.8) | |
| 2 | 46 (39) | 22 (41.5) | 24 (36.9) | |
| 3 | 37 (31.3) | 16 (30.2) | 21 (32.3) | |
| Creatinine>2 (mg/dl) | 13 (9) | 3 (4.5) | 10 (13) | |
| Hemoglobin (mg/dl) | 11.4 (6.5–15.3) | 11.5 (6.7–14.7) | 11.4 (6.5–15.3) | |
| Calcium>10.5 (mg/dl) | 6 (4.2) | 3 (4.5) | 3 (3.9) | |
| Plasma cell leukemia | 4 (2.8) | 2 (3) | 2 (2.6) | |
| Extramedullary plasmacytoma | 27 (18.6) | 12 (17.9) | 15 (19.2) | |
| Hemodialysis | 1 (0.7) | 0 (0) | 1 (1.3) | |
| Type of relapse | ||||
| Biological | 31 (21) | 16 (24) | 15 (19) | |
| Clinical | 82 (57) | 37 (55) | 45 (58) | |
| Aggressive | 32 (22) | 14 (21) | 18 (23) | |
| Interval diagnosis-relapse (months) | 16.4 (0.03–67.5) | 19.2 (0–67.5) | 15.0 (0–65.2) | |
VMP: Bortezomib, Melphalan, and Prednisone; VTP: Bortezomib, Melphalan, and Thalidomide.